Probiotics in Clostridium difficile Infection
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Clostridium difficile infection (CDI) is one of the most prevalent nosocomial infections. A dramatic increase in the incidence and severity of CDI has been noted in the past decade. Current recommendations suggest metronidazole as first-line therapy in mild to moderately severe CDI and oral vancomycin in individuals with severe CDI, or when metronidazole fails or is contradicted. Alterations of the colonic microbiota, usually caused by antimicrobial therapy, seem to play a critical role in CDI pathogenesis. Probiotics are live microorganisms that confer a health benefit to the host, and have been used in CDI. Although a wide variety of probiotics have been studied, the exact role of probiotics in preventing and treating CDI is not clear. In this study, we reviewed the current literature and recommendations on the most commonly studied protiotic agents (Saccharomyces boulardii, Lactobacillus species, and probiotic mixtures) used to prevent or treat CDI. Lactobacillus-containing probiotic mixtures and S. boulardii may be effective in the prevention of CDI in high-risk antibiotic recipients but this finding is based on small, individual studies, and further, larger, well-controlled studies are needed to confirm preliminary positive findings and to better delineate the efficacy of probiotics in CDI prevention or treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microbial Influences in Inflammatory Bowel Diseases
Sartor, R. B. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.11.059 · Cited by 1,927
Decreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/525047 · Cited by 1,010 · cited 2×
“A disturbed colonic microflora leads to a loss of colonization resistance and hence becomes vulnerable to CDI and CDI recurrences.(15,16) The classic example of the importance of colonization resistance to C.”
McFarland, L. V. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00465.x · Cited by 872
Probiotic use in clinical practice: what are the risks?
Boyle, R. J., Robins-Browne, R. M., & Tang, M. L. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1256 · Cited by 776 · cited 2×
“The presence of a central vein catheter, an impaired intestinal barrier, administration of a probiotic through a J-tube, concomitant administration of a broad-spectrum antibiotic that does not cover the probiotic, using probiotics with high mucosal adhesion, and the presence of cardiac valvular disease (LLG only) have…”
Hickson, M., D'Souza, A. L., Muthu, N., Rogers, T. R., Want, S., Rajkumar, C., & Bulpitt, C. J. (2007) · BMJ · doi:10.1136/bmj.39231.599815.55 · Cited by 599 · cited 1×
“It should be noted that 2 recent studies using probiotic mixtures to prevent AAD and CDI were not included in these systematic reviews.(34,36) Both studies are discussed above.”
Saccharomyces cerevisiae Fungemia: An Emerging Infectious Disease
Munoz, P., Bouza, E., Cuenca-Estrella, M., Eiros, J. M., Perez, M. J., Sanchez-Somolinos, M., Rincon, C., Hortal, J., & Pelaez, T. (2005) · Clinical Infectious Diseases · doi:10.1086/429916 · Cited by 462
Gao, X. W., Mubasher, M., Fang, C. Y., Reifer, C., & Miller, L. E. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.11 · Cited by 318 · cited 3×
“Another randomized, double-blind, placebo-controlled dose-ranging study was recently published by Gao et al.(36) A total of 255 adult inpatients were randomized to 3 groups: 2 probiotic capsules per day, 1 probiotic capsule, and 1 placebo capsule per day, or 2 placebo capsules per day.”
Lactobacillus bacteremia and endocarditis: Review of 45 cases
Husni, R. N., Gordon, S. M., Washington, J. A., & Longworth, D. L. (1997) · Clinical Infectious Diseases · doi:10.1086/516109 · Cited by 270
Cited by
Tsilingiri, K., & Rescigno, M. (2013) · Beneficial Microbes · doi:10.3920/bm2012.0046 · Cited by 382
Probiotics for Prevention and Treatment of Diarrhea
Guandalini, S. (2011) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3182257e98 · Cited by 346
Modulatory Effects of Probiotics During Pathogenic Infections With Emphasis on Immune Regulation
Raheem, A., Liang, L., Zhang, G., & Cui, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.616713 · Cited by 302
New Approaches for Bacteriotherapy: Prebiotics, New-Generation Probiotics, and Synbiotics
Patel, R., & DuPont, H. L. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ177 · Cited by 267
Recommendations for Probiotic Use—2015 Update: Proceedings and Consensus Opinion
Floch, M. H., Walker, W. A., Sanders, M. E., Nieuwdorp, M., Kim, A. S., Brenner, D. A., Qamar, A. A., Miloh, T. A., Guarino, A., Guslandi, M., et al. (2015) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000420 · Cited by 119
Metadata
- Authors
- Na, X., & Kelly, C.
- Venue
- Journal of Clinical Gastroenterology
- Published
- 2011-11
- Volume
- 45
- Pages
- S154-S158
- ISSN
- 0192-0790 (ISSN-L)
- OpenAlex
- W2328952959
- Cited by
- 88
- References
- 8
- FWCI
- 6.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.